{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:44:31Z","timestamp":1787021071968,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T00:00:00Z","timestamp":1672185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T00:00:00Z","timestamp":1672185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["54448305"],"award-info":[{"award-number":["54448305"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Acromegaly is a rare chronic endocrine disorder that can lead to significant quality of life (QoL) impairment and persistent symptomatology in both biochemically uncontrolled as well as in cured or controlled patients. We aimed to conduct an observational cross-sectional study investigating the associations between biochemical disease control, associated comorbidities, and symptoms severity on QoL in a cohort of acromegalic patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Thirty-one patients with acromegaly were enrolled in our study. AcroQoL and PASQ (Pain assessed acromegaly symptoms questionnaire) questionnaires were applied to all patients. Information about disease status, associated comorbidities, and other relevant clinical and paraclinical data were gathered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients with uncontrolled acromegaly presented worse QoL and symptoms scores than controlled patients, but the difference was not statistically significant (AcroQoL 57.22 vs 64.04,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05; PASQ 12 vs 16.47,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05). Worse symptoms were significantly associated with impaired QoL (overall symptoms score on PASQ was negatively correlated with AcroQoL total score,\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009\u2212\u00a00.61,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Cardiovascular complications were associated with lower QoL scores, but not with worse symptoms (AcroQoL total score in patients with- versus patients without cardiovascular complications: 54.89 vs 70.14,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Achieving biochemical control of acromegaly might not be enough to reverse the QoL impairment and improve symptomatology in acromegalic patients. While symptoms severity and the presence of cardiovascular complications seem to play an important role in reducing patients QoL, the roles of disease control, diabetes, and pituitary insufficiency are less clear.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41687-022-00537-9","type":"journal-article","created":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T13:05:02Z","timestamp":1672232702000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Associations between paraclinical parameters, symptoms and quality of life in patients with acromegaly: a cross sectional study"],"prefix":"10.1186","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0032-194X","authenticated-orcid":false,"given":"Maximilian Cosma","family":"Gliga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Reti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camelia","family":"Gliga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ionela Maria","family":"Pascanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,28]]},"reference":[{"key":"537_CR1","doi-asserted-by":"publisher","first-page":"519","DOI":"10.5603\/EP.a2017.0041","volume":"68","author":"DA Niculescu","year":"2017","unstructured":"Niculescu DA, Baciu IF, Capatina C et al (2017) Acromegaly treatment in Romania. How close are we to disease control? Endokrynol Pol 68:519\u2013523. https:\/\/doi.org\/10.5603\/EP.a2017.0041","journal-title":"Endokrynol Pol"},{"key":"537_CR2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1210\/er.2009-0033","volume":"31","author":"M Sherlock","year":"2010","unstructured":"Sherlock M, Ayuk J, Tomlinson JW et al (2010) Mortality in patients with pituitary disease. Endocr Rev 31:301\u2013342","journal-title":"Endocr Rev"},{"key":"537_CR3","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/cen.13331","volume":"86","author":"N Kyriakakis","year":"2017","unstructured":"Kyriakakis N, Lynch J, Gilbey SG et al (2017) Impaired quality of life in patients with treated acromegaly despite long-term biochemically stable disease: results from a 5-years prospective study. Clin Endocrinol (Oxf) 86:806\u2013815. https:\/\/doi.org\/10.1111\/cen.13331","journal-title":"Clin Endocrinol (Oxf)"},{"key":"537_CR4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s11102-016-0761-y","volume":"20","author":"I Crespo","year":"2017","unstructured":"Crespo I, Valassi E, Webb SM (2017) Update on quality of life in patients with acromegaly. Pituitary 20:185\u2013188","journal-title":"Pituitary"},{"key":"537_CR5","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1365-2265.2007.02891.x","volume":"67","author":"AN Paisley","year":"2007","unstructured":"Paisley AN, Rowles S, v., Roberts ME, et al (2007) Treatment of acromegaly improves quality of life, measured by AcroQol. Clin Endocrinol (Oxf) 67:358\u2013362. https:\/\/doi.org\/10.1111\/j.1365-2265.2007.02891.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6846","key":"537_CR6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1136\/bmj.305.6846.160","volume":"305","author":"JE Brazier","year":"1992","unstructured":"Brazier JE, Harper R, Jones B, NM, et al (1992) General practice validating the SF-36 health survey questionnaire: new outcome measure for primary care. British Med J 305(6846):160\u2013164","journal-title":"British Med J"},{"key":"537_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1365-2265.2009.03773.x","volume":"73","author":"C Sievers","year":"2010","unstructured":"Sievers C, Br\u00fcbach K, Saller B et al (2010) Change of symptoms and perceived health in acromegalic patients on pegvisomant therapy: a retrospective cohort study within the German pegvisomant observational study (GPOS). Clin Endocrinol (Oxf) 73:89\u201394. https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03773.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"537_CR8","unstructured":"Romanian national health insurance house \u201cCNAS\u201d official website, therapeutic protocols, https:\/\/cnas.ro\/protocoale-terapeutice\/, Accessed 5 Nov 2022"},{"issue":"1","key":"537_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7525-2-1","volume":"2","author":"X Badia","year":"2004","unstructured":"Badia X, Webb SM, Prieto L, Lara N (2004) Acromegaly quality of life questionnaire (AcroQoL). Health Qual Life Outcomes 2(1):1\u20136","journal-title":"Health Qual Life Outcomes"},{"key":"537_CR10","unstructured":"GraphPad Software, La Jolla California USA, www.graphpad.com\"."},{"key":"537_CR11","doi-asserted-by":"crossref","unstructured":"Arosio M, Reimondo G, Malchiodi E, et al (2012) Predictors of morbidity and mortality in acromegaly, an Italian survey","DOI":"10.1016\/j.ando.2012.03.015"},{"key":"537_CR12","doi-asserted-by":"publisher","first-page":"630","DOI":"10.20945\/2359-3997000000193","volume":"63","author":"L Kasuki","year":"2019","unstructured":"Kasuki L, da Rocha P, S, Lamback EB, Gadelha MR, (2019) Determinants of morbidities and mortality in acromegaly. Arch Endocrinol Metab 63:630\u2013637","journal-title":"Arch Endocrinol Metab"},{"key":"537_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1530\/EJE-12-0602","volume":"168","author":"C Sch\u00f6fl","year":"2013","unstructured":"Sch\u00f6fl C, Franz H, Grussendorf M et al (2013) Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German acromegaly register. Eur J Endocrinol 168:39\u201347. https:\/\/doi.org\/10.1530\/EJE-12-0602","journal-title":"Eur J Endocrinol"},{"key":"537_CR14","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/cen.12207","volume":"79","author":"TA Howlett","year":"2013","unstructured":"Howlett TA, Willis D, Walker G et al (2013) Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists. Clin Endocrinol (Oxf) 79:689\u2013699. https:\/\/doi.org\/10.1111\/cen.12207","journal-title":"Clin Endocrinol (Oxf)"},{"key":"537_CR15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1530\/EJE-07-0358","volume":"157","author":"M Bex","year":"2007","unstructured":"Bex M, Abs R, T\u2019Sjoen G et al (2007) AcroBel - the Belgian registry on acromegaly: a survey of the \u201creal-life\u201d outcome in 418 acromegalic subjects. Eur J Endocrinol 157:399\u2013409. https:\/\/doi.org\/10.1530\/EJE-07-0358","journal-title":"Eur J Endocrinol"},{"key":"537_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fendo.2017.00040","volume":"8","author":"VJ Geraedts","year":"2017","unstructured":"Geraedts VJ, Andela CD, Stalla GK et al (2017) Predictors of quality of life in acromegaly: no consensus on biochemical parameters. Front Endocrinol (Lausanne) 8:40","journal-title":"Front Endocrinol (Lausanne)"},{"key":"537_CR17","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.jfma.2019.05.007","volume":"118","author":"FY Tseng","year":"2019","unstructured":"Tseng FY, Chen ST, Chen JF et al (2019) Correlations of clinical parameters with quality of life in patients with acromegaly: Taiwan acromegaly registry. J Formos Med Assoc 118:1488\u20131493. https:\/\/doi.org\/10.1016\/j.jfma.2019.05.007","journal-title":"J Formos Med Assoc"},{"key":"537_CR18","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11102-015-0693-y","volume":"19","author":"PJ Caron","year":"2016","unstructured":"Caron PJ, Bevan JS, Petersenn S et al (2016) Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study. Pituitary 19:149\u2013157. https:\/\/doi.org\/10.1007\/s11102-015-0693-y","journal-title":"Pituitary"},{"key":"537_CR19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4183\/aeb.2021.42","volume":"17","author":"CL Sc\u00e2nteie","year":"2021","unstructured":"Sc\u00e2nteie CL, Leucu\u0163a DC, Ghervan CMV (2021) Quality of life in patients with acromegaly \u2013 a romanian single center cross-sectional study. Acta Endocrinol (Copenh) 17:42\u201350. https:\/\/doi.org\/10.4183\/aeb.2021.42","journal-title":"Acta Endocrinol (Copenh)"},{"key":"537_CR20","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1365-2265.2009.03555.x","volume":"71","author":"C Sievers","year":"2009","unstructured":"Sievers C, Dimopoulou C, Pfister H et al (2009) Prevalence of mental disorders in acromegaly: a cross-sectional study in 81 acromegalic patients. Clin Endocrinol (Oxf) 71:691\u2013701. https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03555.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"537_CR21","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1007\/s12020-014-0521-6","volume":"49","author":"S Vandeva","year":"2015","unstructured":"Vandeva S, Yaneva M, Natchev E et al (2015) Disease control and treatment modalities have impact on quality of life in acromegaly evaluated by acromegaly quality of life (AcroQoL) questionnaire. Endocrine 49:774\u2013782. https:\/\/doi.org\/10.1007\/s12020-014-0521-6","journal-title":"Endocrine"},{"key":"537_CR22","doi-asserted-by":"publisher","first-page":"5369","DOI":"10.1210\/jc.2004-0669","volume":"89","author":"NR Biermasz","year":"2004","unstructured":"Biermasz NR, van Thiel SW, Pereira AM et al (2004) Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J Clin Endocrinol Metab 89:5369\u20135376. https:\/\/doi.org\/10.1210\/jc.2004-0669","journal-title":"J Clin Endocrinol Metab"},{"key":"537_CR23","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000375451","volume":"103","author":"SM Webb","year":"2016","unstructured":"Webb SM, Badia X (2016) Quality of life in acromegaly. Neuroendocrinology 103:106\u2013111. https:\/\/doi.org\/10.1159\/000375451","journal-title":"Neuroendocrinology"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-022-00537-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-022-00537-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-022-00537-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T17:04:07Z","timestamp":1672506247000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-022-00537-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,28]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["537"],"URL":"https:\/\/doi.org\/10.1186\/s41687-022-00537-9","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,28]]},"assertion":[{"value":"12 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the Clinical County Hospital Mures and by the Ethics Committee of \u201cGeorge Emil Palade\u201d University of Medicine, Pharmacy, Science and Technology of Targu Mures (numbers 14775\/10.2020 and 1167\/10.2020). The entire research was conducted in accordance with the ethics principles of the Helsinki declaration. Signed informed consent was obtained from each patient prior to inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no potential conflicts of interest and report no disclosures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"130"}}